MedTrace Logo

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

NCT00933205 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2016-11-30

No results posted yet for this study

Summary

The purpose of this Open Label Safety Study is to provide access to and evaluate the safety and tolerability of TPV/r in treatment-experienced patients with advanced HIV-1 infection who have failed at least two PI-containing regimens, and have limited treatment options.

Conditions

  • HIV Infections

Interventions

DRUG

Tipranavir

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2008-06-30

Countries

  • Belgium
  • Brazil
  • Canada
  • Denmark
  • El Salvador
  • Greece
  • Italy
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00933205 on ClinicalTrials.gov